Compare prices and buy peptides in the Experimental category from every research peptide vendor, supplier and source we index. Updated daily.
Research compounds whose unusual mechanisms or therapeutic areas fit no other category, none of them FDA-approved.
This category holds compounds whose classification does not resolve cleanly against the other eleven: unusual mechanisms, early preclinical status, or a therapeutic area that would distort a better-established class if the compound were filed there. It is deliberately small, and membership is a statement about taxonomy rather than about quality or promise.
None of these compounds holds an FDA approval. All are sold as research material, and this category in particular is not a recommendation of any kind.
A price index only works if compounds are compared against the right peer group. Putting a chimeric anticancer construct in with tissue-repair peptides would make the per-milligram statistics of that category describe something other than what a reader thinks they describe.
Keeping an explicit Experimental class lets vendors selling unusual or boundary compounds be price-compared without contaminating better-defined categories. The trade-off is that this category's own aggregate statistics mean very little, since its members were grouped by exclusion rather than by a shared mechanism.
It means the compound does not classify cleanly against the other eleven categories on this site, because of an unusual mechanism, very early preclinical status, or a therapeutic area that would distort a better-defined class. It is a statement about taxonomy, not about quality, promise or safety. The practical reason for keeping the category is that a price index only works if compounds are compared against the right peer group: filing a chimeric anticancer peptide with tissue-repair peptides would make that category's per-milligram statistics describe something other than what a reader would assume. One consequence is that this category's own aggregate price statistics are close to meaningless, since its members were grouped by exclusion rather than by a shared mechanism.
Because its mechanism is unrelated to the incretin receptor agonism at the core of the GLP Agonist and Weight Loss category, where semaglutide, tirzepatide and retatrutide activate GLP-1 and related receptors. Tesofensine is a phenyltropane small molecule, not a peptide, that inhibits presynaptic reuptake of serotonin, noradrenaline and dopamine, a central monoamine mechanism.
Not as far as its sponsor has published. Saniona's partner Medix applied to COFEPRIS, the Mexican regulator, for approval of tesofensine to treat obesity. A COFEPRIS technical committee issued a favorable opinion in February 2023, but COFEPRIS withheld approval in November 2024, and Medix resubmitted the application in February 2025. Saniona's year-end report for 2025 described the Mexican application as under review. Tesofensine is not FDA-approved in the United States.
A 32-residue chimeric peptide assembled from two parts that do not occur together in nature: residues 12-26 of the HDM-2-binding domain of the p53 protein, fused at its C-terminal end to a membrane-penetrating sequence. The proposed mechanism depends on transformed cells displaying HDM-2 at the plasma membrane in a way non-transformed cells generally do not, so the construct binds, inserts and forms pores selectively. Preclinical reports describe selective lysis of cancer cells with relative sparing of normal cells. PNC-27 has no registered human trial on ClinicalTrials.gov and no FDA approval.
15 vendors tracked by PeptideScouter sell Experimental peptides, across 19 listings covering 3 compounds. The widest Experimental catalogs belong to PSPeptides (2 peptides), Swiss Chems (2 peptides), Alpha Peptides (1 peptide). Prices are normalized to USD per milligram and refreshed daily.
Experimental peptides indexed on PeptideScouter have a median price of $12.12/mg, ranging from $11.45/mg to $12.79/mg across the 3 peptides in the category. Pricing is normalized across vendors and refreshed daily.
PNC-27 carries the lowest median price in the Experimental category at $11.45/mg across 2 listings. Its cheapest in-stock listing is $11.00/mg at PSPeptides. Per-milligram price varies widely between compounds in a category, so the cheapest per mg is not necessarily the cheapest vial or the right compound for a given experiment.
The most widely sold Experimental peptides on PeptideScouter (by vendor count) are: Tesofensine, Adipotide, PNC-27. Each peptide page shows current pricing across every tracked vendor, normalized to USD per milligram.
